JCI table of contents: Nov. 1, 2007

TITLE: Identification of HLA-DR -- bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis

AUTHOR CONTACT:
Jan Wahlstrom
Karolinska University Hospital, Stockholm, Sweden.
Phone: 46-8-5177-0663; Fax: 46-8-5177-5451; Email: .

MEDIA CONTACT:
Katarina Sternudd
Karolinska University Hospital, Stockholm, Sweden.
Email: .

View the PDF of this article at: https://www.the-jci.org/article.php?id=32401

RELATED MANUSCRIPT

TITLE: Portable flanking sequences modulate CTL epitope processing

AUTHOR CONTACT:
Sylvie Le Gall
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Phone: (617) 726-1406; Fax: (617) 726-5411; E-mail: .

MEDIA CONTACT:
Susan McGreevey
Massachusetts General Hospital, Boston, Massachusetts, USA.
(617) 724-2764; E-mail:

David Cameron
Harvard Medical School, Boston, Massachusetts, USA.
Phone: (617) 432-0442; E-mail:

View the PDF of this article at: https://www.the-jci.org/article.php?id=32047

ACCOMPANYING COMMENTARY

TITLE: The saga of MHC-bound peptides: a renaissance for antigen presentation?

AUTHOR CONTACT:
Luc Teyton
The Scripps Research Institute, La Jolla, California, USA.
Phone: (858) 784-2728; Fax: (858) 784-8805; Email: .

View the PDF of this article at: https://www.the-jci.org/article.php?id=33997

ONCOLOGY: OX40L helps trigger anti-cancer immune responses

Many researchers are currently trying to develop ways to harness the ability of immune cells known as dendritic cells (DCs) to induce antitumor immune responses as a potential therapeutic approach for the treatment of cancer. New data generated in mice by Toshiaki and colleagues from Tohoku University, Japan, has indicated that expression of a protein known as OX40L is important if DCs are to trigger an antitumor immune response. Dapeng Zhou from the University of Texas MD Anderson Cancer Center, Houston, discusses the therapeutic implications of these data in an accompanying commentary.

In the study, it was shown that DC expression of OX40L was critical if the DCs were to induce antitumor immune responses when injected into mice. Furthermore, if DCs engineered to express high levels of OX40L were injected into pre-established tumors, tumor growth was suppressed by an antitumor immune response mediated by NKT cells and CD4+ Th cells. Further analysis indicated that the intratumoral NKT cells produced high levels of the soluble factor IFN-gamma, leading the authors to suggest that OX40L on DCs might couple innate to adaptive antitumor immunity.